IP Library Granted Patent US 11,866,556
Granted Patent B2
US 11,866,556 · App. 17/166,909 · Granted Jan 9, 2024

Process for efficient cross-linking of hyaluronic acid

Inventor: Morgan Karlsson (Almunge, SE)
Assignee: Galderma Holding SA
C08J3/24A61K8/735A61K9/06A61K31/728A61K47/36A61L27/20A61Q19/08C08B37/0072C08J3/075C08L5/08A61K2800/91A61L2430/34C08J2305/08C08L2201/54C08L2203/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,866,556
App. No.
17/166,909
Granted
Jan 9, 2024
Kind
B2
Abstract

A process for manufacturing a cross-linked hyaluronic acid (HA) gel product is comprising the steps of: (a) preparing an aqueous mixture of HA and a cross-linking agent selected from multiepoxides and diepoxides; wherein the HA is dissolved in an aqueous solution containing 1-10% (w/w) inorganic hydroxide; and wherein the dissolved HA constitutes more than 10% (w/w) of the final mixture; and (b) subjecting the aqueous mixture to cross-linking conditions to allow the dissolved HA to react with the cross-linking agent so as to obtain a cross-linked HA gel product.

Claims (23)

1. A process for manufacturing a cross-linked hyaluronic acid (HA) gel product, the process comprising:

(a) obtaining an aqueous mixture of HA and a diepoxide cross-linking agent selected from the group consisting of 1,4-butanediol diglycidyl ether (BODE), 1,2-ethanediol diglycidyl ether (EDDE) and diepoxyoctane, wherein the HA is dissolved in an aqueous solution comprising 2.5-4% (w/w) inorganic hydroxide, and wherein the dissolved HA constitutes 33-35% (w/w) of the aqueous mixture; and

(b) cross-linking the aqueous mixture at 10-75° C. to obtain the cross-linked HA gel product, wherein the HA is cross-linked in a single step, and wherein the cross-linked HA gel product has a GelC of 90% or greater.

2. The process according to claim 1 , wherein the aqueous solution of (a) comprises 2.5% to 3% (w/w) inorganic hydroxide.

3. The process according to claim 1 , wherein the aqueous mixture of (a) comprises 33% (w/w) HA.

4. The process according to claim 1 , wherein the aqueous mixture of (a) comprises 35% (w/w) HA.

5. The process according to claim 1 , wherein the crosslinking is performed at 15-35° C.

6. The process according to claim 1 , wherein the crosslinking is performed at 20-2 5 ° C.

7. The process according to claim 1 , wherein the crosslinking occurs at room temperature.

8. The process according to claim 1 , wherein the crosslinking is performed for at least 2 hours.

9. The process according to claim 1 , wherein the crosslinking is performed for 4-36 h.

10. The process according to claim 1 , wherein the crosslinking is performed at 15-35° C. for 2-40 h so as to obtain the crosslinked HA gel product.

11. The process according to claim 1 , wherein the crosslinking is performed at 15-35° C. for 16-24 h so as to obtain the crosslinked HA gel product.

12. The process according to claim 1 , wherein the diepoxide crosslinking agent is 1,4-butanediol diglycidyl ether (BDDE).

13. The process according to claim 1 , wherein the diepoxide crosslinking agent is 1,2-ethanediol diglycidyl ether (EDDE).

14. The process according to claim 1 , wherein the diepoxide crosslinking agent is diepoxyoctane.

15. The process according to claim 1 , wherein the diepoxide crosslinking agent is not completely consumed in the crosslinking.

16. The process according to claim 1 , further comprising (c) isolating the crosslinked HA product.

17. The process according to claim 16 , wherein the isolating comprises precipitating the HA gel product.

18. The process according to claim 1 , wherein the cross-linked HA gel product exhibits an elastic modulus of 800 to 1200 Pa.

19. The process according to claim 1 , wherein the cross-linked HA gel product is sterilized.

20. The process according to claim 1 , wherein the cross-linked HA gel product exhibits an elastic modulus of 1000 to 1200 Pa.

21. The process according to claim 1 , wherein the cross-linked HA gel product has a GelC of 95% or greater.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2024
From: OHRLUND, AKE
To: GALDERMA HOLDING SA
Reel/Frame 066715/0198 →
CHANGE OF ADDRESS Recorded Jun 27, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 061113/0710 →
ASSET TRANSFER AGREEMENT Recorded Feb 4, 2021
From: GALDERMA SA
To: NESTLE SKIN HEALTH SA
Reel/Frame 055989/0177 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: KARLSSON, MORGAN
To: GALDERMA SA
Reel/Frame 055145/0651 →
CHANGE OF NAME Recorded Feb 4, 2021
From: NESTLÉ SKIN HEALTH SA
To: GALDERMA HOLDING SA
Reel/Frame 055221/0770 →